Bioventus Signs Agreement To Sell Its Advanced Rehabilitation Business To Accelmed Partners; Deal Includes Total Cash Consideration Of $45M Including $25M In Cash At Close And Up To $20M In Post-Closing Earn-Outs
Portfolio Pulse from Benzinga Newsdesk
Bioventus has entered into an agreement to sell its Advanced Rehabilitation business to Accelmed Partners for a total cash consideration of $45 million. The deal includes $25 million in cash at closing and up to $20 million in post-closing earn-outs.
October 01, 2024 | 1:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Bioventus is selling its Advanced Rehabilitation business to Accelmed Partners for $45 million, which includes $25 million in cash at closing and up to $20 million in earn-outs.
The sale of the Advanced Rehabilitation business is a significant move for Bioventus, providing immediate cash inflow and potential future earnings. This could positively impact Bioventus's financial position and stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100